The Zhitong Finance App learned that Gacos-B (01167) rose more than 23% in the afternoon. As of press release, it rose 19.51% to HK$1.96, with a turnover of HK$11.3326 million.
According to the news, Gacos previously announced that the new drug clinical trial application (IND) for its self-developed P53 Y220C activator JAB-30300 has been approved by the US Food and Drug Administration (FDA). According to reports, currently only one similar project of the P53 Y220C activator in the world is in the first clinical phase. The JAB-30300 is expected to be one of the first products to be launched.
In addition, Gacos Pharmaceuticals announced in mid-February that its self-developed SHP2 inhibitor JAB-3312 was approved for phase III clinical trials in China in combination with the KRAS G12C golerese inhibitor. This incident marks that SHP2, a target that has not yet been developed, has officially entered phase III clinical trials, a critical step until it is approved for marketing.